Biogen says 'misinformation' is fueling controversy over Alzheimer's drug
Biogen on Thursday mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the company’s head of research and development releasing an open letter to the Alzheimer’s community that took direct aim at critics of approval.
Al Sandrock, the R&D chief and an architect of many of Biogen’s successes, wrote that the purpose of the letter was to correct “misinformation” about the drug.
“Unfortunately, Aduhelm’s approval has been the subject of extensive misinformation and misunderstanding,” Sandrock wrote. “It is normal for scientists and clinicians to discuss data from experiments and clinical trials, to debate, and to disagree, on the interpretation of data. That is how science advances and we welcome these discussions. Recently, however, there has been a turn outside the boundaries of legitimate scientific deliberation.”
The company’s chief executive, Michel Vounatsos, echoed those comments on a call with investors. “I want to be clear that Biogen stands behind the integrity of the review process,” Vounatsos said. He said he understood concerns about the drug’s $56,000 price, and promised to make sure that patients would be able to …
More on: www.statnews.com